News >

Lead Investigator Discusses Pegilodecakin/PD-1 Inhibitor Combination in NSCLC

Brandon Scalea
Published: Tuesday, Aug 21, 2018

Edward B. Garon, MD

Edward B. Garon, MD
The combination of pegilodecakin (AM0010) and anti–PD-1 therapy demonstrated durable responses in patients with non–small cell lung cancer (NSCLC), according to findings presented at the 2018 ASCO Annual Meeting.

In the phase I study, pegilodecakin, which is a long-acting PEGylated Interleukin (IL)-10, was administered subcutaneously at 10 to 20 µg/kg daily. Five patients received pembrolizumab (Keytruda) at 2 mg/kg every 3 weeks and 29 received nivolumab (Opdivo) at 3 mg/kg every 2 weeks.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication